We are live on ! Find out more
CDIO icon

Cardio Diagnostics
CDIO

35 hedge funds and large institutions have $52.4M invested in Cardio Diagnostics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 35 → 35 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

4.15% less ownership

Funds ownership: 68.36% → 64.21% (-4.1%)

5% less capital invested

Capital invested by funds: $55.2M → $52.4M (-$2.81M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OCAM
Owl Creek Asset Management
New York
+$2.5M
2
RL
RPO LLC
Connecticut
+$1.44M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$229K
4
OFG
OTA Financial Group
New York
+$27.9K

Top Sellers

Rank Fund Capital Flow
1
MSU
Mizuho Securities USA
New York
-$3.98M
2
BFM
Boothbay Fund Management
New York
-$2.39M
3
WAM
Wolverine Asset Management
Illinois
-$647K
4
GCL
Glazer Capital LLC
New York
-$249K
5
SSA
Schonfeld Strategic Advisors
New York
-$178K

CDIO Hedge Fund Activity: Q3 2022 in Review

35 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Cardio Diagnostics (CDIO) for Q3 2022, worth a combined $52.4M — down 5.1% from $55.2M a quarter earlier.

Fund positioning in CDIO was balanced in Q3 2022: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 4 trimmed.

The largest buyer was Owl Creek Asset Management, opening a new position worth an estimated $2.5M. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $3.98M sold.

  • 35 institutional investors held Cardio Diagnostics (CDIO) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $52.4M of Cardio Diagnostics stock for Q3 2022, down 5.1% quarter-over-quarter.
  • 3 funds opened new Cardio Diagnostics positions in Q3 2022 and 3 closed out, a net change of 0 holders.
  • The largest Cardio Diagnostics buyer in Q3 2022 was Owl Creek Asset Management, an estimated $2.5M added.
  • The largest Cardio Diagnostics seller in Q3 2022 was Mizuho Securities USA, an estimated $3.98M sold.

Based on aggregated 13F filings for Q3 2022.